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1ercutaneous Coronary
ntervention Related Delay
n ST-Segment Elevation
yocardial Infarction Patients
e read with interest Antman’s (1) editorial comment on the
iewpoint taken by Terkelsen et al. (2).
Antman (1) highlights the following sentence from the 2007
pdated ST-segment elevation myocardial infarction guidelines:
If EMS is not capable of administering pre-hospital fibrinolysis
nd the patient is transported to a non-PCI capable hospital, the
oor-to-needle time should be within 30 min for patients for
hom fibrinolysis is indicated; If EMS is not capable of admin-
stering pre-hospital fibrinolysis, and the patient is transported to
PCI-capable hospital, the EMS arrival-to-balloon time should
e within 90 min” (3). Antman (1) does not justify why the clock
tarts ticking at 2 different stages of the diagnostic process
epending on whether in-hospital fibrinolysis or primary percuta-
eous coronary intervention (PCI) is performed.
Antman (1) states that “Terkelsen and colleagues argue without
roviding data that the typical pre-hospital delay includes 10 min
t the scene and 10 min for transportation.” In the ER–TIMI 19
Early Retavase–Thrombolysis In Myocardial Infarction 19) trial
y Morrow et al. (4), the pre-hospital delay was even longer, which
nly corroborates our point that the updated guidelines favor the
se of fibrinolysis. In patients receiving in-hospital fibrinolysis, a
ubstantial pre-hospital delay does not have any consequences,
hereas any pre-hospital delay is devastating for implementing
rimary PCI as the preferred therapy.
The PCAT-2 (Primary Coronary Angioplasty vs. Thrombolysis-2)
eta-analysis by Boersma et al. (5) is questioned and Antman (1)
tates that “a biologically implausible pattern was observed in those
llocated to fibrinolysis.” “Why should the efficiency with which a
ospital can implement a primary PCI strategy have any bearing
n the mortality rate when patients receive a fibrinolytic?” asks
ntman (1), and obviously it has not. It is important to remember
hat the PCAT-2 meta-analysis (5) comprises data from 22 trials,
nd certainly PCI-related delay varies according to trial design
transfer or nontransfer for PCI) and from center to center. Also
ortality in the fibrinolytic-treated patients varies according to the
mplemented selection criteria and trial design. This is the obvious
xplanation and the overall finding from the PCAT-2 meta-
nalysis (5) is still that primary PCI, as compared with fibrinolysis,
s associated with a significant mortality reduction irrespective of
CI-related delays (up to 120 min).
Antman (1) uses data from a National Registry of Myocardial
nfarction registry-study by Pinto et al. (6) to comment on the
agnitude of the effects of prolonged PCI-related delays. Use of
egistries or observational data to evaluate PCI-related delay is
uestionable, and it should be appreciated that the National
egistry of Myocardial Infarction includes 5% of ST-segmentlevation myocardial infarction patients in the U.S. and at best
ompares a near optimal fibrinolytic strategy (92% given fibrin-
pecific lytics) with an inferior primary PCI strategy (PCI centers
erforming on average 21 primary PCI procedures a year with a
edian door-to-balloon time of 116 min and a first-door-to-
alloon time of 180 min in patients transferred for PCI).
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eply
thank Dr. Terkelsen and colleagues for their interest in my
ditorial comment (1). In response to the points raised by
erkelsen et al. (2) it is worth noting:
. Clearly the Writing Committee (3) was addressing a systemsgoal when recommending that if the emergency medical service
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April 7, 2009:1244–7(EMS) is not capable of administering pre-hospital fibrinolysis
and the patient is transported to a nonpercutaneous coronary
intervention (PCI)–capable hospital, the door-to-needle time
should be within 30 min. It is not logical to “start the clock” for
administration of a fibrinolytic in an EMS setting that is not
capable of delivering such a treatment. In contrast, if EMS is
not capable of administering pre-hospital fibrinolysis and the
patient is transported to a PCI-capable hospital, the EMS
arrival-to-balloon time should be within 90 min, emphasizing
the system goal of communication to the PCI-capable hospital
to shorten the delays for arrival of the critical personnel to
perform the procedure.
. The field and transport times in the U.S., in general, are much
longer than those cited by Terkelsen et al. (2), as evidenced by
the findings from ER–TIMI 19 (Early Retavase–Thrombolysis In
Myocardial Infarction 19) trial (4). The Writing Committee (3)
stressed the need for systems efforts to reduce time to reperfu-
sion with the full appreciation, in contrast to the opinion of
Terkelsen et al. (2), that pre-hospital delays are harmful to both
patients treated with fibrinolysis as well as those treated by PCI.
. The explanation regarding the unusual pattern of mortality in
the fibrinolytic-treated patients in the PCAT-2 (Primary Cor-
onary Angioplasty vs. Thrombolysis-2) meta-analysis (5) actu-
ally underscores the concern about using it to buttress the
statement that primary PCI, as compared with fibrinolysis, is
associated with a significant mortality reduction irrespective of
PCI-related delays. The mixing of trial designs and failure to
account for patient characteristics remain substantial shortcom-
ings of the PCAT-2 analysis.
. The statements about the National Registry of Myocardial
Infarction are not correct. The National Registry of Myocardial
Infarction is the largest voluntary myocardial infarction database
in the world and provides data from 2,157 unique hospitals,
more than one-third of all U.S. acute care hospitals. In contrast
to the numbers cited by Terkelsen et al. (2), between 1990 and
2006, there was a switch in the distribution of reperfusion
methods used so that by 2006, 43.2% of patients received
primary PCI and 27.6% received fibrinolysis (6). The real-world
experience from the National Registry of Myocardial Infarction
and the analysis from Pinto et al. (7) remain important
contributions to our global understanding of the complex
decision making in reperfusion for ST-segment elevation myo-
cardial infarction. Age, location of infarction, and time from
onset of occlusion are key determinants of prognosis and it is
logical that they should be factored into decision making about
treatment for ST-segment elevation myocardial infarction.
erkelsen et al. (2) perseverate on technical details of selection of
reperfusion strategy rather than address the need for re-
ngineering of systems of care. Without attention to such systems
fforts it is unlikely we will see further clinically meaningful
hortening of the time from occlusion of a patient’s coronary artery
o restoration of antegrade blood flow in that vessel.
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icrovolt T-Wave Alternans
s There Anything
hat Can Be Done to Save It?
he sobering results reported in the contribution of Chow et al.
1), published in the November 11, 2008, issue of the Journal, calls
or a serious and in-depth reassessment of microvolt T-wave
lternans (MTWA) technology for its role in the identification of
atients with ischemic and nonischemic cardiomyopathy and
ho are most likely to benefit from implantable cardioverter-
efibrillator (ICD) deployment. Previous observational studies
ave concluded that MTWA predicts arrhythmic events and
herapeutic ICD shocks, in patient populations with diverse
ardiac pathologies. In contrast, the prospective study under
onsideration (1)—which comprised 575 patients who met
ADIT-II (Multicenter Automatic Defibrillator Implantation
rial II) criteria for an ICD implantation (post-myocardial infarc-
ion status and an ejection fraction of 30%), had an MTWA
ssessment before the ICD implantation, and were followed for at
east 2 years—showed that the risk of suffering a ventricular
rrhythmic event was no different between the patients with a
egative MTWA test and those with a non-negative MTWA test,
lthough the latter had higher total mortality. What is more
isconcerting is that this study is published simultaneously with
